Astellas Pharma, a provider of pharmaceutical products, agreed to acquire Xyphos Biosciences, a privately held development-stage biotechnology company, for $665m. "The innovative technology in development at Xyphos fits perfectly in advancing our immuno-oncology strategy to create and deliver value for patients. Combining this technology with our capabilities in cell therapy that we have been working on so far, we can create next-generation high-function cells and maximize the value of our technology. We look forward to working with Xyphos' superb team to advance and expand their clinical development programs to bring their novel therapeutics to patients," Kenji Yasukawa, Astellas President and CEO.